Genenta Science (NASDAQ:GNTA) Stock Falls 5.9% – Time to Sell?

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA)’s stock price dropped 5.9% during mid-day trading on Thursday. The company traded as low as $0.7101 and last traded at $0.7101. Approximately 53,588 shares traded hands during trading, a decline of 17% from the average session volume of 64,763 shares. The stock had previously closed at $0.7550.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Genenta Science Trading Up 10.6%

The business’s 50 day simple moving average is $0.97 and its 200 day simple moving average is $1.10.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Genenta Science stock. SmartHarvest Portfolios LLC increased its stake in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) by 656.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 134,447 shares of the company’s stock after acquiring an additional 116,666 shares during the period. SmartHarvest Portfolios LLC owned approximately 0.57% of Genenta Science worth $90,000 as of its most recent SEC filing. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

About Genenta Science

Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company developing cell and gene therapies for cancer. The company’s approach uses a patient’s own hematopoietic stem cells, genetically modified outside the body to produce therapeutic proteins and deliver them to the tumor microenvironment.

Genenta’s lead investigational product, Temferon, is designed to generate interferon-alpha within solid tumors. The therapy is being studied primarily in glioblastoma, an aggressive form of brain cancer, with the goal of concentrating treatment in the tumor while limiting exposure to healthy tissues.